Related Experiment Video

Updated: May 11, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

GLP-1 agonists in type 1 diabetes

Jeremy Pettus1, Irl Hirsch, Steven Edelman

  • 1University of California San Diego, San Diego, CA, USA; Veterans Affairs Hospital, La Jolla, CA, USA.

Clinical Immunology (Orlando, Fla.)
|May 7, 2013
PubMed

Insights

Glucagon-like peptide 1 agonists show promise for type 1 diabetes by improving beta cell health. Further research is needed to explore their potential to modify the immune response in type 1 diabetes patients.

Area of Science:

  • Immunology
  • Endocrinology
  • Diabetes Research

Background:

  • Type 1 diabetes lacks therapies targeting the immune response.
  • Glucagon-like peptide 1 (GLP-1) agonists show potential for beta cell health and mass.
  • Current GLP-1 agonists benefit glucose control in type 2 diabetes.

Purpose of the Study:

  • To review preclinical and clinical data of GLP-1 agonists.
  • To assess the potential immunological benefits of GLP-1 agonists for type 1 diabetes.
  • To evaluate the clinical benefits of GLP-1 agonists in type 1 diabetes.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of clinical trial data for GLP-1 agonists.
  • Examination of immunological mechanisms related to GLP-1 action.

Main Results:

  • GLP-1 agonists demonstrate positive effects on beta cell health and mass in preclinical models.
  • Existing GLP-1 agonists provide clinical glucose control benefits in type 2 diabetes patients.
  • Emerging data suggests potential immunomodulatory effects relevant to type 1 diabetes.

Conclusions:

  • GLP-1 agonists represent a potential therapeutic avenue for type 1 diabetes.
  • Further investigation into the immunomodulatory effects of GLP-1 agonists is warranted.
  • Clinical trials are needed to confirm the efficacy and safety of GLP-1 agonists in type 1 diabetes.
Keywords:
GLP-1Glucagon-like peptide 1Type 1 diabetes

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...